Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A C Wolff

Showing results (41-50 of 43) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 43 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 11, 2023
Association of HER2DX with pathological complete response and survival outcomes in HER2-positive breast cancerG Villacampa, N M Tung, S Pernas, et al.
ESMO Open|October 17, 2024
Final analysis of the ALTTO trial: adjuvant trastuzumab in sequence or in combination with lapatinib in patients with HER2-positive early breast cancer [BIG 2-06/NCCTG N063D (Alliance)]E de Azambuja, M Piccart-Gebhart, S Fielding, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 23, 2026
Including tumor-infiltrating lymphocytes into the PREDICT prognostic model for triple-negative breast cancer survivalY Wang, D Drubay, S F Jonas, et al.
Pageof 5

Showing results (41-50 of 43) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 43 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 11, 2023
Association of HER2DX with pathological complete response and survival outcomes in HER2-positive breast cancerG Villacampa, N M Tung, S Pernas, et al.
ESMO Open|October 17, 2024
Final analysis of the ALTTO trial: adjuvant trastuzumab in sequence or in combination with lapatinib in patients with HER2-positive early breast cancer [BIG 2-06/NCCTG N063D (Alliance)]E de Azambuja, M Piccart-Gebhart, S Fielding, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 23, 2026
Including tumor-infiltrating lymphocytes into the PREDICT prognostic model for triple-negative breast cancer survivalY Wang, D Drubay, S F Jonas, et al.
Pageof 5